Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.

Q3 Medicine

Gastroenterology and Hepatology From Bed to Bench Pub Date : 2024-01-01 DOI:10.22037/ghfbb.v17i3.2978

Milad Khabbazpour, Masoud Tat, Ashraf Karbasi, Mohammad Ali Abyazi, Ghazal Khodadoustan, Zohreh Heidary, Majid Zaki-Dizaji

{"title":"Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review.","authors":"Milad Khabbazpour, Masoud Tat, Ashraf Karbasi, Mohammad Ali Abyazi, Ghazal Khodadoustan, Zohreh Heidary, Majid Zaki-Dizaji","doi":"10.22037/ghfbb.v17i3.2978","DOIUrl":null,"url":null,"abstract":"Aim: A systematic review was conducted to summarize the methylated circulating tumor DNA (ctDNA) markers reported over the last decade for early detection of colorectal cancer (CRC) and to identify the main technical challenges that are impeding their clinical implementation.Background: CRC is a major cause of cancer deaths worldwide, but early detection is key for successful treatment. Non-invasive methods such as methylated ctDNA testing show promise for improving detection and monitoring of CRC.Methods: A comprehensive search was performed using Web of Science, PubMed, and Scopus up to December 30, 2023, limited to articles published in the last 10 years (after 2012), while including advanced adenoma/stage 0 or stage I/II samples in biomarker validation.Results: After identifying 694 articles, removing duplicates and screening titles, abstracts, and full texts, a total of 62 articles were found to meet the inclusion criteria. Among the single biomarkers, MYO1-G, SEPT9, SDC2, and JAM3 revealed the highest sensitivity for polyps and stage I/II CRC. For multi-biomarkers with suitable sensitivity, combinations of SFRP1, SFRP2, SDC2, PRIMA1, or ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, VIM or ZFHX4, ZNF334, ELOVL2, UNC5C, LOC146880, SFMBT2, GFRA1 were identified for polyps and stage I/II CRC.Conclusion: Enhancing sensitivity and specificity of molecular screening methods is crucial for improving CRC detection. Identifying a select few valuable biomarkers is key to reducing costs, despite challenges posed by low ctDNA levels in plasma, particularly in early-stage cancers.","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"17 3","pages":"225-240"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413380/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology and Hepatology From Bed to Bench","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/ghfbb.v17i3.2978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: A systematic review was conducted to summarize the methylated circulating tumor DNA (ctDNA) markers reported over the last decade for early detection of colorectal cancer (CRC) and to identify the main technical challenges that are impeding their clinical implementation.

Background: CRC is a major cause of cancer deaths worldwide, but early detection is key for successful treatment. Non-invasive methods such as methylated ctDNA testing show promise for improving detection and monitoring of CRC.

Methods: A comprehensive search was performed using Web of Science, PubMed, and Scopus up to December 30, 2023, limited to articles published in the last 10 years (after 2012), while including advanced adenoma/stage 0 or stage I/II samples in biomarker validation.

Results: After identifying 694 articles, removing duplicates and screening titles, abstracts, and full texts, a total of 62 articles were found to meet the inclusion criteria. Among the single biomarkers, MYO1-G, SEPT9, SDC2, and JAM3 revealed the highest sensitivity for polyps and stage I/II CRC. For multi-biomarkers with suitable sensitivity, combinations of SFRP1, SFRP2, SDC2, PRIMA1, or ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, VIM or ZFHX4, ZNF334, ELOVL2, UNC5C, LOC146880, SFMBT2, GFRA1 were identified for polyps and stage I/II CRC.

Conclusion: Enhancing sensitivity and specificity of molecular screening methods is crucial for improving CRC detection. Identifying a select few valuable biomarkers is key to reducing costs, despite challenges posed by low ctDNA levels in plasma, particularly in early-stage cancers.

查看原文本刊更多论文

基于血液 DNA 甲基化的结直肠癌早期检测方法的进展：系统性最新综述。

目的：我们进行了一项系统性综述，总结了过去十年间报道的用于早期检测结直肠癌（CRC）的甲基化循环肿瘤 DNA（ctDNA）标记物，并确定了阻碍其临床应用的主要技术挑战：背景：结直肠癌是全球癌症死亡的主要原因，但早期检测是成功治疗的关键。甲基化ctDNA检测等非侵入性方法有望改善对CRC的检测和监测：方法：使用 Web of Science、PubMed 和 Scopus 对截至 2023 年 12 月 30 日的文章进行了全面检索，仅限于过去 10 年（2012 年之后）发表的文章，同时将晚期腺瘤/0 期或 I/II 期样本纳入生物标记物验证：在识别了 694 篇文章、去除重复文章并筛选了标题、摘要和全文后，发现共有 62 篇文章符合纳入标准。在单一生物标记物中，MYO1-G、SEPT9、SDC2 和 JAM3 对息肉和 I/II 期 CRC 的敏感性最高。对于具有合适灵敏度的多生物标志物，SFRP1、SFRP2、SDC2、PRIMA1 或 ALX4、BMP3、NPTX2、RARB、SDC2、SEPT9、VIM 或 ZFHX4、ZNF334、ELOVL2、UNC5C、LOC146880、SFMBT2、GFRA1 的组合被确定为息肉和 I/II 期 CRC 的灵敏度：结论：提高分子筛查方法的灵敏度和特异性对改进 CRC 检测至关重要。尽管ctDNA在血浆中的含量较低，尤其是在早期癌症中，但找出少数有价值的生物标志物是降低成本的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastroenterology and Hepatology From Bed to Bench Medicine-Gastroenterology

CiteScore

2.30

自引率

0.00%

发文量